Cargando…

Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review

Severe hypertriglyceridemia accounts for up to 7% of all cases of acute pancreatitis. Heparin and insulin activate lipoprotein lipase (LPL), thereby reducing plasma triglyceride levels. However, the safety and efficacy of heparin and insulin in the treatment of hypertriglyceridemia-associated acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchay, Mohammad Shafi, Farooqui, Khalid J., Bano, Tarannum, Khandelwal, Manoj, Gill, Harmandeep, Mithal, Ambrish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118862/
https://www.ncbi.nlm.nih.gov/pubmed/28225998
http://dx.doi.org/10.1590/2359-3997000000244
Descripción
Sumario:Severe hypertriglyceridemia accounts for up to 7% of all cases of acute pancreatitis. Heparin and insulin activate lipoprotein lipase (LPL), thereby reducing plasma triglyceride levels. However, the safety and efficacy of heparin and insulin in the treatment of hypertriglyceridemia-associated acute pancreatitis have not been well established yet. We successfully used heparin and insulin as first-line therapy in four consecutive patients with acute pancreatitis secondary to hypertriglyceridemia. In a literature search, we revised almost all reports published to date of patients managed successfully with this combination. Heparin and insulin appear to be a safe, effective, and inexpensive first-line therapy for hypertriglyceridemia-associated acute pancreatitis.